We tested associations of plasma p-tau217 and tau-PET with patient demographics, amyloid-PET burden, and APOE-ε4 carriership, as well as with two markers of putatively downstream pathophysiological processes: brain atrophy and cognitive impairment. Here, MAPT is linked to Cognitive impairment.